Michael Avery talks to a panel about the first mRNA vaccine technology transfer hub in SA
24 June 2021 - 15:36
byBusiness Day TV
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
As Gauteng faces a third wave of Covid-19 infections, the slow pace of SA’s vaccination programme is being brought into stark — and deadly — relief. A major component of the slow rollout is access to vaccines. And although Covax has distributed almost 40-million doses to 110 countries and economies, vaccine nationalism, vaccine diplomacy and severe supply constraints have so far prevented Covax from realising its full potential.
The World Health Organisation (WHO) and its Covax partners are working with an SA consortium comprising Biovac, Afrigen Biologics and Vaccines, a network of universities and the Africa Centres for Disease Control and Prevention (CDC) to establish its first Covid-19 mRNA vaccine technology transfer hub.
Michael Avery talks to Dr Martin Friede, co-ordinator of the Initiative for Vaccine Research at the WHO and the lead of the long-term sustainable manufacturing workstream, Covax manufacturing task force; Dr Morena Makhoana, Biovac CEO; and Dr Stavros Nicolaou, head of the health working group for B4SA (Business 4 SA) about the first mRNA hub in SA.
Michael Avery talks to a panel about the first mRNA vaccine technology transfer hub in South Africa.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Covid-19 Business Watch
WATCH: The first mRNA hub in SA
Michael Avery talks to a panel about the first mRNA vaccine technology transfer hub in SA
As Gauteng faces a third wave of Covid-19 infections, the slow pace of SA’s vaccination programme is being brought into stark — and deadly — relief. A major component of the slow rollout is access to vaccines. And although Covax has distributed almost 40-million doses to 110 countries and economies, vaccine nationalism, vaccine diplomacy and severe supply constraints have so far prevented Covax from realising its full potential.
The World Health Organisation (WHO) and its Covax partners are working with an SA consortium comprising Biovac, Afrigen Biologics and Vaccines, a network of universities and the Africa Centres for Disease Control and Prevention (CDC) to establish its first Covid-19 mRNA vaccine technology transfer hub.
Michael Avery talks to Dr Martin Friede, co-ordinator of the Initiative for Vaccine Research at the WHO and the lead of the long-term sustainable manufacturing workstream, Covax manufacturing task force; Dr Morena Makhoana, Biovac CEO; and Dr Stavros Nicolaou, head of the health working group for B4SA (Business 4 SA) about the first mRNA hub in SA.
Michael Avery talks to a panel about the first mRNA vaccine technology transfer hub in South Africa.
Or listen to the full audio:
Subscribe for free episodes: iono.fm | Apple Podcasts | Spotify | Pocket Casts | Player.fm
ADÈLE SULCAS: Turning the tide on Covid crisis
US to share millions of Covid-19 shots with poorer countries
What’s holding up the vaccine rollout?
SA teams up with France and WHO for vaccine skills transfer
Decision on Coronavac vaccine at advanced stage, says medicines health regulator
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
ADÈLE SULCAS: Turning the tide on Covid crisis
FDA to add warning to mRNA vaccines over rare heart inflammation in young
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.